Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.85, along ...

Medtronic (NYSE:MDT – Free Report) had its price objective decreased by Wells Fargo & Company ... Its Cardiovascular ...

Medtronic (NYSE:MDT – Free Report) had its price target increased by Barclays ... Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and ...

Here's a look at Medtronic's past performance and the resulting price change ... Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices ...

Medtronic (NYSE: MDT) Q2 2025 Earnings Call Nov 19, 2024, 8:00 a.m. ET ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

For now, though, the story out of Marlborough remains focused on relentless growth: Revenue is expected to rise this year by ...

I'm Ryan Weispfenning, vice president and head of Medtronic investor relations ... performance from franchises like TAVR, PFA, leadless pacemakers, diabetes, spine, and neuromodulation, just ...

Presentation Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations at Medtronic Good morning. I'm Ryan ...

This might be surprising considering the damage caused by its bet-the-farm, $27 billion deal in 2006 for pacemaker company ... intense competition from J&J, Medtronic, and Abbott Laboratories ...